Abstract
Purpose:
Both intravitreal pegaptanib with laser therapy and intravitreal bevacizumab monotherapy have been found to be more efficacious than laser therapy alone in prospective, randomized, controlled clinical trials.
Results:
The use of pegaptanib with laser therapy was efficacious in 91.2% compared with 69.0% in controls. The use of bevacizumab monotherapy was efficacious in 95.7% compared with 78.1% in controls.
Conclusions:
The use of anti-vascular endothelial growth factor therapy for retinopathy of prematurity has been shown to be efficacious, without toxicity reported to date; however, the best drug and dose which allows greatest efficacy with fewest recurrences and without toxicity must be determined.
Publication types
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage*
-
Aptamers, Nucleotide / administration & dosage*
-
Combined Modality Therapy
-
Humans
-
Infant, Newborn
-
Intravitreal Injections
-
Laser Coagulation*
-
Lasers, Semiconductor / therapeutic use*
-
Prospective Studies
-
Retinopathy of Prematurity / classification
-
Retinopathy of Prematurity / drug therapy
-
Retinopathy of Prematurity / surgery
-
Retinopathy of Prematurity / therapy*
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Angiogenesis Inhibitors
-
Aptamers, Nucleotide
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
pegaptanib